Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

54 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Clinical evaluation of two dosages and schedules of ifosfamide in combination with cisplatin in neo-adjuvant chemotherapy of patients with advanced (stage III-IV) head and neck squamous cell carcinoma: a phase II randomized study.
Mantovani G, Ghiani M, Lai P, Maccio A, Dessi D, Succu G, Massa D, Curreli L, Mulas C, Esu S, Proto E, Cadeddu G, Tore G. Mantovani G, et al. Among authors: dessi d. Oncol Rep. 1998 Nov-Dec;5(6):1499-505. doi: 10.3892/or.5.6.1499. Oncol Rep. 1998. PMID: 9769395 Clinical Trial.
Tumor-associated lymphocytes (TAL) are competent to produce higher levels of cytokines in neoplastic pleural and peritoneal effusions than those found in sera and are able to release into culture higher levels of IL-2 and IL-6 than those released by PBMC.
Mantovani G, Macciò A, Versace R, Pisano M, Lai P, Esu S, Ghiani M, Dessì D, Turnu E, Santona MC, et al. Mantovani G, et al. Among authors: dessi d. J Mol Med (Berl). 1995 Aug;73(8):409-16. doi: 10.1007/BF00240140. J Mol Med (Berl). 1995. PMID: 8528743
Tumor-associated lympho-monocytes from neoplastic effusions are immunologically defective in comparison with patient autologous PBMCs but are capable of releasing high amounts of various cytokines.
Mantovani G, Macciò A, Pisano M, Versace R, Lai P, Esu S, Massa E, Ghiani M, Dessì D, Melis GB, Del Giacco GS. Mantovani G, et al. Among authors: dessi d. Int J Cancer. 1997 May 29;71(5):724-31. doi: 10.1002/(sici)1097-0215(19970529)71:5<724::aid-ijc6>3.0.co;2-t. Int J Cancer. 1997. PMID: 9180137
Neo-adjuvant chemo-(immuno-)therapy of advanced squamous-cell head and neck carcinoma: a multicenter, phase III, randomized study comparing cisplatin + 5-fluorouracil (5-FU) with cisplatin + 5-FU + recombinant interleukin 2.
Mantovani G, Gebbia V, Airoldi M, Bumma C, Contu P, Bianchi A, Ghiani M, Dessì D, Massa E, Curreli L, Lampis B, Lai P, Mulas C, Testa A, Proto E, Cadeddu G, Tore G. Mantovani G, et al. Among authors: dessi d. Cancer Immunol Immunother. 1998 Nov;47(3):149-56. doi: 10.1007/s002620050515. Cancer Immunol Immunother. 1998. PMID: 9829840 Free PMC article. Clinical Trial.
54 results